Cargando…

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer

Nonmuscle invasive bladder cancer is associated with a high risk of recurrence as well as progression to muscle-invasive disease. Therefore, adequate visualization and identification of malignant lesions as well as complete resection are critical. Traditional white-light cystoscopy is limited in its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahill, Ellen M., Chua, Kevin, Doppalapudi, Sai Krishnaraya, Ghodoussipour, Saum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Special Topic: Advances in bladder cancer therapy: Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527925/ https://www.ncbi.nlm.nih.gov/pubmed/36204358 http://dx.doi.org/10.1097/CU9.0000000000000142

Ejemplares similares

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer
por: Iemura, Yusuke, et al.
Publicado: (2023)

A radiation-related second primary gastrointestinal stromal tumor in the bladder
por: Hori, Mai, et al.
Publicado: (2023)

Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer
por: Wang, Delin, et al.
Publicado: (2023)

Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy
por: Jiang, Ying, et al.
Publicado: (2023)

Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer
por: Gadelkareem, Rabea Ahmed, et al.
Publicado: (2023)

The association between postvoid residual and response to standard therapy in male and female patients with non–muscle-invasive bladder cancer
por: Di Gianfrancesco, Luca
Publicado: (2023)

A retrospective analysis of the factors associated with increased risk of readmission within 30 days after primary transurethral resection of bladder tumor
por: Jindal, Tarun, et al.
Publicado: (2023)

Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2023)

The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer
por: Wu, Zhang-Song, et al.
Publicado: (2022)

Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review
por: Kronstedt, Shane, et al.
Publicado: (2022)

Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer
por: Veeratterapillay, Rajan, et al.
Publicado: (2021)

Complete transurethral resection of bladder tumor before radical cystectomy is not a risk factor for organ-confined bladder cancer: A case-control study
por: Yuan, Xiaoxu, et al.
Publicado: (2022)

Role of multiparametric magnetic resonance imaging in the diagnosis and staging of urinary bladder cancer
por: Shalaby, Essam A., et al.
Publicado: (2022)

Clinical characteristics and treatment outcomes of patients with small cell carcinoma of the urinary bladder
por: Muranaka, Takashi, et al.
Publicado: (2022)

Collision nodal metastasis of bladder cancer and melanoma: The first reported case and literature review
por: Sanguedolce, Francesca, et al.
Publicado: (2022)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma
por: Al-Delaimy, Wael K., et al.
Publicado: (2022)

Updates on enhanced recovery after surgery for radical cystectomy
por: Lee, Grace, et al.
Publicado: (2022)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial
por: Yu, Ge, et al.
Publicado: (2023)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2udovrk735p7aej18t79bg6sd9